Topic: [CROWDSALE] [LIVE NOW] DEAD IS BAD! Save your ASSets with Agemeter. - page 2. (Read 3234 times)

While cryptocurrencies and blockchain markets are growing like crazy - your days are coming to an end because of aging.
Without any doubt market cap of a dead investor is ZERO. Protect your crypto investments by helping to fight YOUR aging and meet science Superstar George Church (Bitcoins accepted) !

As laboratories around the world work towards translating experimental anti-aging findings to human treatments, a self administered functional age test to validate interventions that aim to slow or reverse the aging process is greatly needed.

Our goal is to develop a low-cost, modular touch screen device for integrating multiple cognitive & biometric assessment technologies. This can be used to gather, analyze, and compare data in aging research scientific studies, and thereby increase the pace of longevity research.



The AgeMeterTM device will measure functional biomarkers of participants, estimating the age at which a person physically functions, enabling researchers to validate measurements from genetic and biochemical aging interventions and reliably compare results across subjects, studies and approaches.

Many laboratories have published results indicating the reversal or delay of various biomarkers of aging in model organisms and human cells, including cellular biomarkers such as telomere length, epigenome methylation status, expression of proteins specific to senescent cells and others, as well as morphological and functional tests, such as appearance, gait and balance, memory tests, etc. Thus far, however, there has been no fully integrated approach that can easily collect a variety of different data points from human participants, reliably correlating the output to functional age and comparing this against chronological age.

Being able to easily evaluate the effectiveness of a potential aging treatment in this way will allow longevity research to proceed at a faster rate, because meaningful data in regards to lifespan effect can be gathered in the middle of a study, not just at the end.

For this reason some of the world’s top longevity researchers have shown their support specifically for our project, as evinced by their following quotes:



Harvard Scientists Dr. David Sinclair and Dr. George Church are two of the world’s most famous and honored researchers in the field, and they understand well the need for reliable biomarkers of aging. As a glimpse of their exciting work, Dr. Sinclair’s lab recently caused muscle tissue of 60 year old equivalent mice to resemble 20 years old after one week of injections of the molecule NMN, and here is a video of Dr. Church describing a gene altering technique accomplishing age reversal in a sample of his own cells.



Dr. Aubrey de Grey, noted longevity advocate and Chief Science Officer of the SENS Research Foundation also understands that reliable physiological biomarkers for aging will be an important part of assessing potential anti-aging treatments. SENS has done pioneering work in classifying the types of damage that accrue in our bodies with age, some of which you will be familiar with if you have supported previous campaigns on Lifespan.io.



Also needed is the ability to reliably correlate the functional age, or phenotype, of participants with their genotype. This would greatly facilitate the search for genomic variations that may point the way towards uncovering the fundamental differences in rates of aging among different individuals. Toward that end, Dr. George Church and colleagues have been the initiators of the Personal Genome Project, whose goal is to obtain quality whole genome sequences of up to one thousand volunteers that would then be made publicly available to researchers. They are keenly interested in having such an easily deployed functional assay made available for such research.



The AgeMeterTM will be a modernized successor to the H-SCAN functional age test that was originally developed in 1990 to assess physical biomarkers of aging. Building upon this work, our new AgeMeter device will test the following functional biomarkers, each accompanied by a guided demonstration video enabling users to complete tests without staff supervision:

1. Auditory reaction time (Fozard et al. 1994, Wolkorte et al. 2014)
2. Highest audible pitch
3. Vibrotactile sensitivity (sense of touch)
4. Visual reaction time (Woods et al. 2015)
5. Muscle movement time (Spirduso et al. 1975, Spirduso 1980, Ebaid et al. 2017)
6. Lung: forced vital capacity (Lee et al. 2017)
7. Lung: forced expiratory volume, 1 sec (Anstey et al. 2005, Lee et al. 2017)
8. Decision reaction time (Spirduso et al. 1975, Anstey et al. 2005)
9. Decision movement time (Spirduso et al. 1975)
10. Memory
11. Alternate button tapping (muscle coordination)
12. Visual perception (Anstey et al. 2005, Lockhart and Shi 2010)
  
General references: Hochchild 1989, Hochchild 1989, Klatz 2003, Butler et al. 2004  

In the original device these parameters were then statistically correlated with the ages of 2,462 subjects, and based on this accumulated data new users received a report that estimated their functional vs. chronological age:





The first iteration of the AgeMeterTM will be an updated version of this original H-SCAN functional age test, utilizing a touch screen tablet and modernized software. We also plan to research additional functional biomarkers of aging for use in future versions.



For our initial goal we will purchase and configure prototype hardware that will include a touchscreen tablet computer and required peripherals to perform the above-mentioned physiological and cognitive tests.

We will then create appropriate user interface software for each test, along with software to manage the collection of test result data. The initial breakdown of development costs will be as follows:



Prototype Hardware: 20%
 To obtain and configure tablet computer, and peripheral test devices such as a spirometer to measure lung air capacity.


User Interface: 30%
 Programming of the tests themselves, and instructions interface for test takers.


Initial participant testing: 35%
 Handling the logistics of sampling initial set of ~2500 users of various ages and backgrounds.


Software Functions and Database: 15%
 Programming the collection and storage of data in a cloud database and associated service costs.




The development pipeline of the initial goal will consist of:


1. Prepare detailed specifications and overall design of the device. The categories of these specifications include the Tablet, Biometric Testing Software, User Interface Software, Peripheral Interface Software, Database Development, Cloud Software Development for data aggregation and basic data visualizations, and Video Test Assistant Software to instruct users on proper testing.
 [Estimated delivery: 1 month after campaign completion]

2. Build a functional prototype AgeMeter device for measuring aging biomarkers based on the above specifications.
 [Estimated delivery: 3 months after campaign completion]

3. Build multiple AgeMeter units, based on the performance of our initial prototype, for use by researchers to create the initial database of aging base line values.
 [Estimated delivery: 6 months after campaign completion]

4. Recruit researchers to test approximately 2,500 human participants in order to develop statistical models and functional age calculation algorithms, based on the results obtained for various ages, genders, education levels, ethnicities, etc. There will also be an opt-out process for participants to anonymously store their data in a cloud-based server so that the database of test values will automatically grow as new values are uploaded.
 [Estimated delivery: 12 months after campaign completion]
 

The fulfillment of the above steps will culminate in a functional AgeMeter device suitable for aging research use, which will allow a test to be compared against baseline averages for analysis.




Stretch Goal 1 — $50,000
User Accounts and Personal Data History – The Quantified Self
Reaching this stretch goal will allow us to create software for a user account system for each test participant. This will enable users to store and access multiple test results, and therefore analyze the progression of one’s metrics over time and in response to potential anti-aging interventions.



To create this system we will obtain a Production Web Host Cloud subscription and set up a web server to manage user account access. This will include new data visualizations and reports that go beyond those created for the initial goal and that will be tailored to your individual metrics. Users will also be able to download their raw data and a summary report on how they compare to baseline averages. This data could then be contributed to the Personal Genome Project or Open Humans if a user participates in those projects.




Stretch goal 2 — $80,000:
 Additional Biomarker Development
Reaching this stretch goal will allow us to pursue the development of additional biomarker tests for future versions of the AgeMeter, increasing its ability to collect and analyze data.



 For example we want to add computer vision analysis to track ability to hold an object steady within a target area and move between various targets fluidly, and measure how this ability alters with age. Another test we’d like to add is fingertip pulse oximeter measurements to detect blood oxygenation, both at baseline and in response to mental and physical exertion. Most ambitiously we also want to integrate Functional Near-Infrared Spectroscopy (fNIRS) (for example  McKendrick R, Parasuraman R and Ayaz H (2015), Front. Syst. Neurosci. 9:27) into our data gathering, as a measure of blood flow and oxygenation in the brain. Think of this as a safe and more portable fMRI that bounces a frequency of near infrared light up to approximately 4 centimeters into your brain!



An example of fNIRS imaging:  McKendrick R, Parasuraman R and Ayaz H (2015), Front. Syst. Neurosci. 9:27

 The addition of more biomarkers such as these into future versions of the AgeMeter will make the entire suite of tests even more helpful to researchers, and we hope you’ll help us make their inclusion a reality.





Elliott holds a B.A. degree in Biochemical Sciences from Harvard University. He has been a chemist at General Foods, director of a government funded program: The Technology Commercialization Center in Washington DC, and a computer programmer. He is also the founder of a company that has 2 patents and 2 patents pending for rapid battery charging technologies. Elliott’s lifelong interest in science began at the age of 10, when he started experimenting with photo processing and electronics. From 1999 to 2013, he represented and eventually became sole distributor for the original H-SCAN functional age test used by medical practices and other care providers worldwide, personally selling the H-SCAN devices to customers in North America, South America, Europe, Asia and Africa.



David holds a B.S. degree in General Engineering from the University of Illinois, Urbana-Champaign, and is fluent in German.  He earned an E.I.T. license in the State of Illinois, a step towards professional licensure. David has designed industrial machinery, ag components, and worked in the automation industry for over six years. He also has five years of IT experience working at the University of Illinois, as a visiting research programmer. He has coordinated a multi-year, multi-million dollar automotive engineering data project abroad in Germany. His most recent commercial coding project was developing a mobile, web based, aerospace launch control monitoring system for a Fortune 500 company.



Alexander Hoekstra holds a BS degree in Genomics and Molecular Genetics from Michigan State University. Alex was one of the principal organizers of the 2015 PGP Conference. He manages the PGP at the laboratory of Dr. George Church, in the Genetics Department of Harvard Medical School. Other affiliations are Michigan State Univ (Microbiology & Molecular Genetics Dept), National Institutes of Health (NIDDK), Wayne State University (Center for Molecular Medicine & Genetics).